Key Highlights

  • Pre-market trading on Friday, November 13, 2026 put the shares at USD 0.0991, a fall of 7.64%, far beneath the USD 1.00 minimum bid price that Nasdaq sets.
  • Nasdaq's letter, dated November 2, 2026 and disclosed November 4, provides runway through May 3, 2027 for restoring compliance, meaning a closing bid of USD 1.00 or higher on 10 consecutive Business days.
  • Published figures had the stock at USD 0.4816 on October 20, 2026, so today's quote sits about 79% lower (calculated), with roughly 42.21 million shares outstanding.
  • Over the trailing twelve months, sales totaled USD 24.49 million, a 23.1% decrease, and losses reached USD 15.95 million; a September report nonetheless described first-half 2026 Revenue up 25%.

Nasdaq Bid-Price Letter Sits Behind the Slide

Baird Medical Investment Holdings (NASDAQ:BDMD) is the subject of the most recent company-specific item, a Nasdaq deficiency letter dated November 2, 2026. The letter, which became public on November 4, says the bid price has remained beneath USD 1.00 per Listing Rule 5550(a)(2). The notice does not trigger delisting, and the shares keep trading under the symbol BDMD. The firm has 180 calendar days, running through May 3, 2027, and could qualify for a second 180-day window if it meets the other listing standards and files a cure plan. Searches found nothing dated November 12 or 13, so the 7.64% pre-market fall is treated as a reaction on light volume.

Microwave Ablation Products, Overseas Registrations and Partnerships

Baird Medical Investment Holdings (NASDAQ:BDMD) develops minimally invasive devices that ablate solid tumors. Its flagship is a microwave system cleared by the FDA for soft tissue ablation, now being introduced in the United States chiefly for benign thyroid nodules. In August 2026 the company teamed up with Alpmed on irreversible electroporation technology, while registrations or first procedures have been reported in Pakistan, Vietnam, Argentina and Egypt. China, where its largest base sits, is also covered by distribution agreements. So far the share price has not recovered toward USD 1.00 despite these developments, and the material reviewed did not include a specific cure plan.

Trailing Losses, Cure Options and Dilution Exposure

On the fundamentals side, Baird Medical Investment Holdings (NASDAQ:BDMD) reports sales over the past twelve months of USD 24.49 million, a 23.1% decline, and a Bottom Line showing a USD 15.95 million loss, which equals USD 0.53 per share in published figures. A September 3 report pointed to first-half 2026 revenue up 25% alongside positive net income, which runs counter to the trailing figures and calls for care in interpreting either. Cash was not located. With the shares near USD 0.10, a reverse split or new Equity Financing could be used to cure the bid deficiency, and either route can dilute holders or disrupt them. Thin pre-market trading also means the quoted price can reverse quickly.

Where Things Stand

The decline is best understood as continued pressure following the Nasdaq bid-price letter, with no fresh announcement behind it. Baird Medical Investment Holdings (NASDAQ:BDMD) was quoted at USD 0.0991 in pre-market trading on November 13, 2026, far below USD 1.00 and roughly 79% under its October 20 level (calculated). Some markets are expanding, yet the trailing loss remains USD 15.95 million. Upcoming signposts are the cure plan, any reverse split proposal, the next financial report and the May 3, 2027 deadline.